{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:02:56Z","timestamp":1793134976413,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jiac.2022.04.027","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T07:56:29Z","timestamp":1655366189000},"page":"1235-1241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid"],"prefix":"10.1016","volume":"28","author":[{"given":"Hiroshige","family":"Mikamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7369-2173","authenticated-orcid":false,"given":"Makoto","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kusachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fujimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carisa","family":"De Anda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2022.04.027_bib1","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2022.04.027_bib2","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2022.04.027_bib3","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1001\/jama.2016.16226","article-title":"Trend in ventilator-associated pneumonia rates between 2005 and 2013","volume":"316","author":"Metersky","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2022.04.027_bib4","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.46.1800516","article-title":"Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017","volume":"23","author":"Suetens","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jiac.2022.04.027_bib5","series-title":"Guidance for industry hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment","year":"2020"},{"key":"10.1016\/j.jiac.2022.04.027_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-0711-5-7","article-title":"Ventilator associated pneumonia and infection control","volume":"5","author":"Alp","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiac.2022.04.027_bib7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ajic.2017.09.005","article-title":"The epidemiology of nonventilator hospital-acquired pneumonia in the United States","volume":"46","author":"Giuliano","year":"2018","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jiac.2022.04.027_bib8","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1017\/ice.2015.167","article-title":"Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification","volume":"36","author":"Micek","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jiac.2022.04.027_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 1","key":"10.1016\/j.jiac.2022.04.027_bib10","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/653053","article-title":"Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"51","author":"Jones","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.04.027_bib11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s10156-012-0411-x","article-title":"Hospital-acquired pneumonia in Japan may have a better mortality profile than HAP in the United States: a retrospective study","volume":"18","author":"Iwata","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.04.027_bib12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jiac.2015.12.019","volume":"22","author":"Mikasa","year":"2016","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.04.027_bib13","unstructured":"Japanese Society of Chemotherapy\/Japanese Association for Infectious Diseases. Practical guidelines for the management and treatment of infections caused by MRSA, 2019 Edition. (Japanese)."},{"key":"10.1016\/j.jiac.2022.04.027_bib15","series-title":"US prescribing information","year":"2019"},{"key":"10.1016\/j.jiac.2022.04.027_bib16","series-title":"Summary of product characteristics","year":"2020"},{"key":"10.1016\/j.jiac.2022.04.027_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan \u2013 Results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2022.04.027_bib18","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/AAC.05354-11","article-title":"Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers","volume":"56","author":"Housman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2022.04.027_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab032","article-title":"A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia","author":"Wunderink","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2022.04.027_bib20","series-title":"Performance Standards for Antimicrobial susceptibility testing. CLSI supplement M100","year":"2019"},{"key":"10.1016\/j.jiac.2022.04.027_bib21","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0","year":"2019"},{"key":"10.1016\/j.jiac.2022.04.027_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.jiac.2022.04.027_bib23","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/infdis\/jiy578","article-title":"Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"219","author":"Talbot","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2022.04.027_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2169\/internalmedicine.47.0577","article-title":"HAP study group. Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of first-line antibiotics in Japan","volume":"47","author":"Watanabe","year":"2008","journal-title":"Intern Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22001416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22001416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:03:56Z","timestamp":1761159836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22001416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1341321X22001416"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.04.027","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}